Suppressing tumors by attenuating CD4+ CD25+ FoxP3+ Treg-mediated immune suppression and eliciting persistent antitumor immunity against cancer (5.64 μg once a day for 25 days, i.p.) Here, FOXP3 is linked to cancer.